Revolutionizing Material Optimization with Full Stack
AI-Driven Innovation
Our Partners
Microsoft for Non-profits
Google for Non-profits
Sewa International
City of Peoria, Arizona
At Ryniant Sciences, our journey to innovation is driven by a relentless pursuit of groundbreaking discoveries in the fields of AI integrated therapeutics and health informatics development.
We are passionate about pushing the boundaries of science and technology to create impactful solutions that transform the landscape of healthcare. While engaging in democratization of the industry as a whole.
Our Business Model
Ryniant Sciences operates multiple subsidiary companies. This approach is commonly referred to as the vant model of company development. Ryniant’s subsidiary model enhances efficiency by combining specialized research with a shared AI core. Each subsidiary focuses on a specific field while leveraging Ominor for drug discovery. This structure optimizes resources, accelerates breakthroughs, and scales innovations globally. 🚀
Ominor Platform
Ominor is the AI backbone of Ryniant Sciences’ therapeutic development—an end-to-end cost effective & affordable platform for rapid binding, ADMET, and molecule generation that outperforms traditional pipelines and democratizes drug discovery. It is the foundation of Ryniant's therapeutic development planned subsidiaries and our flagship product
Calrivis
Calrivis develops AI driven applications to democratize bioinformatics diagnostics through the cut in manpower required--allowing more patients to be gieven diagnostics faster and more affordable than before
Bluvia
Bluvia develops AI tools to aid entities in predicting the risk to public health as a result of environmental contamination through the use of machine learning and laboratory data analysis--making risk prediction cheaper and easier than ever before. Bluvia is a unique endeavor and is pushing the boundaries of AI applications in the real world.
Advancing Molecular Engineering Through Efficiency
AI-Driven Solutions
Rare Diseases
50%
Material Engineering timeline cut
60%
Drug Development Cost Cut
5
Industry & academic Experts backing
Potential Impact
With our commitment to keeping our researched tools open access, we can significantly reduce barriers to entry for the drug development industry
- Join us
Join our team and be on the forefront of development for novel tools for biotech democratization & innovation , public health improvement, and health informatics. Contact us for opportunities.
Get Involved
Please go to the dedicated donations page to get more goal specific choices for donations.